Online citations, reference lists, and bibliographies.
← Back to Search

Contemporary Analysis Of Prognostic Factors In Patients With Unresectable Malignant Pleural Mesothelioma

A. Billè, L. Krug, K. Woo, V. Rusch, M. Zauderer
Published 2016 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Introduction: Previous prognostic scoring systems for malignant pleural mesothelioma (MPM) included patients managed surgically and predated the use of pemetrexed. We analyzed prognostic factors in a contemporary cohort of patients with unresectable MPM who received pemetrexed‐based chemotherapy. Methods: This single‐institution analysis included patients with MPM who were managed nonsurgically from 2000 to 2013. Variables correlated with overall survival (OS) included sex, performance status (PS), asbestos exposure, tumor laterality, histology, clinical stage, initial positron emission tomography maximum standardized uptake value, hemoglobin level, platelet count, lymphocyte count, white cell and neutrophil counts, treatment type, and clinical benefit from treatment. OS was analyzed by the Kaplan‐Meier method, and significance (p < 0.05) of prognostic factors was analyzed by the log‐rank test and Cox regression. Results: A total of 191 patients met the study criteria: median age 71 years (range 46–90), 147 men (77%), 128 epithelioid tumors (67%), and 157 cases of stage III or IV MPM (82%). Median OS for all patients was 13.4 months. According to a univariate analysis, histology (p < 0.001), platelet count (≤450,000 versus >450,000, p < 0.001), initial PS (0–1 versus ≥2), maximum standardized uptake value (≤8.1 versus >8.1, p = 0.037), and lymphocyte counts (p = 0.019) were associated with OS. According to a multivariable analysis, only histology, platelet count, and PS were independent prognostic factors. Epithelioid histology, PS, and elevated lymphocyte count at diagnosis were significantly associated with clinical benefit from first‐line chemotherapy. Conclusions: Our results confirm the significance of elements of the Cancer and Leukemia Group B and European Organisation for Research and Treatment of Cancer prognostic scoring systems, identify factors associated with clinical benefit from chemotherapy, and emphasize the impact of histology and clinical benefit of chemotherapy on outcomes.
This paper references
10.1097/JTO.0b013e31826915f1
Initial Analysis of the International Association For the Study of Lung Cancer Mesothelioma Database
V. Rusch (2012)
10.1016/J.JTCVS.2004.10.034
Integrated computed tomography-positron emission tomography in patients with potentially resectable malignant pleural mesothelioma: Staging implications.
J. Erasmus (2005)
10.1016/J.THORSURG.2004.06.011
Epidemiology, biologic behavior, and natural history of mesothelioma.
L. Zellos (2004)
10.1093/jjco/hyv039
A new prognostic index for overall survival in malignant pleural mesothelioma: the rPHS (regimen, PS, histology or stage) index.
Yuki Kataoka (2015)
SUVmax, maximum standardized uptake value; ULN, upper limit of normal
10.1378/CHEST.113.3.723
Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B.
J. Herndon (1998)
10.1097/JTO.0b013e3182519d96
High SUVmax on FDG-PET Indicates Pleomorphic Subtype in Epithelioid Malignant Pleural Mesothelioma: Supportive Evidence to Reclassify Pleomorphic as Nonepithelioid Histology
Kyuichi Kadota (2012)
10.1016/j.lungcan.2014.03.006
Vinorelbine and gemcitabine as second- or third-line therapy for malignant pleural mesothelioma.
M. Zauderer (2014)
10.1016/S0022-5223(03)00207-1
Positron emission tomography defines metastatic disease but not locoregional disease in patients with malignant pleural mesothelioma.
R. Flores (2003)
10.1097/JTO.0000000000000181
Supplementary Prognostic Variables for Pleural Mesothelioma
H. Pass (2014)
10.1016/j.lungcan.2010.05.016
Imaging in pleural mesothelioma: a review of imaging research presented at the 9th International Meeting of the International Mesothelioma Interest Group.
A. Nowak (2010)
10.1016/j.humpath.2015.02.006
Prognostic factors in malignant pleural mesothelioma.
B. Davidson (2015)
10.1038/bjc.2014.312
Prognostic factors in elderly patients with malignant pleural mesothelioma: results of a multicenter survey
G. Ceresoli (2014)
10.1200/JCO.2003.11.136
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
10.1200/JCO.1998.16.1.145
Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience.
D. Curran (1998)



This paper is referenced by
10.1007/978-3-319-96244-3
Caring for Patients with Mesothelioma: Principles and Guidelines
M. Hesdorffer (2019)
10.2147/LCTT.S102113
Clinical staging of malignant pleural mesothelioma: current perspectives
M. Bonomi (2017)
10.1634/theoncologist.2018-0501
Systemic Therapy Use and Outcomes After Relapse from Preoperative Radiation and Extrapleural Pneumonectomy for Malignant Pleural Mesothelioma.
S. V. Soldera (2018)
10.22034/APJCP.2017.18.8.2073
Survival in Good Performance Malignant Pleural Mesothelioma Patients; Prognostic Factors and Predictors of Response
M. Rahouma (2017)
10.3389/fonc.2019.00740
Liquid Biopsy in Malignant Pleural Mesothelioma: State of the Art, Pitfalls, and Perspectives
I. Cavallari (2019)
10.1183/13993003.00349-2018
ERS/EACTS statement on the management of malignant pleural effusions
A. Bibby (2018)
10.1245/s10434-018-6385-x
The C-Reactive Protein/Albumin Ratio is a Novel Significant Prognostic Factor in Patients with Malignant Pleural Mesothelioma: A Retrospective Multi-institutional Study
Shinkichi Takamori (2018)
10.1371/journal.pone.0190653
Sialic acid-binding lectin from bullfrog eggs inhibits human malignant mesothelioma cell growth in vitro and in vivo
T. Tatsuta (2018)
10.1080/09537104.2016.1246712
Pretreatment thrombocytosis as a significant prognostic factor in malignant mesothelioma: a meta-analysis
Y. Zhuo (2017)
10.21873/anticanres.13719
Determination of Mesothelin Levels in Pleural Effusion Does Not Help Predict Survival of Patients With Malignant Pleural Mesothelioma
V. Fontana (2019)
10.1016/B978-0-323-44284-8.00021-1
Malignant and Borderline Mesothelial Tumors of the Pleura
M. R. Wick (2011)
10.5505/tjo.2017.1542
Clinicopathological and Survival Characteristics of Malignant Pleural Mesothelioma: A Single-Institutional Experience
Şule Karabulut Gül (2017)
10.3389/fonc.2020.00445
Circulating Epigenetic Biomarkers in Malignant Pleural Mesothelioma: State of the Art and critical Evaluation
L. Ferrari (2020)
10.1016/j.cllc.2017.01.008
The Controlling Nutritional Status Score Is a Significant Independent Predictor of Poor Prognosis in Patients With Malignant Pleural Mesothelioma
Shinkichi Takamori (2017)
10.1371/journal.pone.0229299
Prognostic value of SUVmax on 18F-fluorodeoxyglucose PET/CT scan in patients with malignant pleural mesothelioma
J. Lim (2020)
10.5301/tj.5000521
A Case of Pseudoachalasia Hiding a Malignant Pleural Mesothelioma
F. Branchi (2016)
10.1111/ajco.12788
PD‐L1 expression associated with worse survival outcome in malignant pleural mesothelioma
B. Nguyen (2018)
10.1016/j.stemcr.2017.02.005
Stem Cell Factor-Based Identification and Functional Properties of In Vitro-Selected Subpopulations of Malignant Mesothelioma Cells
Walter Blum (2017)
10.1183/13993003.00953-2019
ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma
A. Scherpereel (2020)
10.1007/978-3-319-96244-3_10
Mesothelioma and Physical Therapy
Richard D. Hemingway (2019)
10.5772/intechopen.91769
Predictive and Prognosis Factors of Clinical Utility in Mesothelioma
Rodríguez-Cid Jeronimo Rafael (2020)
10.1038/bjc.2017.20
Comparison of outcomes following a cytological or histological diagnosis of malignant mesothelioma
Sanjeevan Muruganandan (2017)
10.12816/0042979
A Retrospective Analysis of Epidemiology Prognostic Factor and Response of Treatment of Malignant Pleural Mesothelioma
Dalia Abd El-Ghany El-Khodary (2018)
10.3389/fonc.2018.00091
New Perspectives on Diagnosis and Therapy of Malignant Pleural Mesothelioma
Marika Rossini (2018)
10.1016/j.ejca.2020.03.002
Genomic analysis in short- and long-term patients with malignant pleura mesothelioma treated with palliative chemotherapy.
F. Torricelli (2020)
10.1093/ejcts/ezy258
ERS/EACTS statement on the management of malignant pleural effusions
A. Bibby (2019)
10.21037/JTD.2019.04.93
Pleurectomy/decortication and hyperthermic intrathoracic chemoperfusion using cisplatin and doxorubicin for malignant pleural mesothelioma.
L. Klotz (2019)
10.1093/ejcts/ezaa158
ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma.
I. Opitz (2020)
Semantic Scholar Logo Some data provided by SemanticScholar